MacroGenics, Inc. (MGNX)

Over the past six months, MacroGenics' stock price has fluctuated, with a significant decline of approximately 35.79% between February 3, 2025, and January 30, 2026. As of February 7, 2026, the stock was trading at $1.81, within a 52-week range of $0.99 to $2.95. The Q3 2025 earnings report on November 12, 2025, showed an EPS of $0.27 and revenue of $73 million, surpassing estimates. Despite this, the stock had previously dropped approximately 33% since an earlier "Hold" rating, reflecting financial challenges and reliance on episodic milestones. The company is forecast to remain unprofitable over the next three years, with revenue expected to decline.

The provided information does not contain specific details regarding demand seasonality for MacroGenics, Inc.'s products and services. Demand for its products is typically driven by medical need, clinical trial outcomes, regulatory approvals, and market adoption rather than traditional seasonal patterns. The company's revenue streams are described as uncertain and reliant on episodic milestones.

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing monoclonal antibody-based therapeutics for cancer treatment. The company operates in the Healthcare sector, specifically in the Pharmaceuticals: Major and Biotechnology & Medical Research industries. MacroGenics generates product candidates from its proprietary suite of next-generation antibody-based technology platforms. Key products and pipeline candidates include MARGENZA (margetuximab-cmkb), Lorigerlimab, MGC026, MGC028, MGD024, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936 and MGD014.

MacroGenics, Inc. is headquartered in Rockville, Maryland, United States.

MacroGenics aims to develop, manufacture, and commercialize life-changing medicines for cancer patients, emphasizing expertise in protein engineering and a commitment to excellence. The company supports ESG initiatives aligned with its "Living Values" to build a safe, environmentally responsible, and ethical business. The company's stock performance, including a significant drop and ongoing financial challenges, could indirectly influence public perception and investor confidence. The company's reliance on episodic milestones and minimal product revenues has been noted as a factor making it less attractive for new investors.

MacroGenics (NASDAQ: MGNX) is primarily owned by institutional shareholders (72.71%), with insiders holding 37.79% and retail investors holding 0.00%. Major institutional owners include Bellevue Group AG, Armistice Capital LLC, The Vanguard Group, Inc., Frazier Life Sciences Management, L.P., Acadian Asset Management LLC, Millennium Management LLC, Wasatch Global Investors Inc, Renaissance Technologies LLC and BlackRock Institutional Trust Company, N.A.. Notable individual owners (insiders) include Target N. V. Biotech, Scott Koenig, TPG Group Holdings Sbs Advisors Inc and Alta Biopharma Partners III LP.